Navigation Links
Rotavirus vaccine developed in India demonstrates strong efficacy
Date:5/14/2013

the social innovation partnership and ensuring the highest standards for the vaccine.

The randomized, double-blind, placebo-controlled Phase III clinical trial enrolled 6,799 infants in India (aged six to seven weeks at the time of enrolment) at three sitesthe Centre for Health Research and Development, Society for Applied Studies (SAS) in New Delhi; Shirdi Sai Baba Rural Hospital, KEM Hospital Research Centre in Vadu, Pune; and Christian Medical College (CMC) in Vellore. The Clinical Operations Management Unit headed by Dr Nita Bhandari at SAS oversaw the day-to-day coordination and logistical complexities of this multi-site study and played a pivotal role in the conduct of this trial. The Principal Investigators were Dr Temsunaro Rongsen-Chandola at SAS, Dr Ashish Bavdekar at KEM, and Dr Gagandeep Kang at CMC.

The Data Safety Monitoring Board (DSMB), an independent group of experts established to protect the participating infants' rights and needs during the Phase III trial, determined that the trial met the highest standards for ethics and patient care and complied with international standards for good clinical practices.

Bharat Biotech previously announced a price of US$ 1.00/dose (or approximately INR 54/dose) for ROTAVAC and will soon file for registration of the vaccine in India. If licensed by the Drugs Controller General of India (DCGI), the vaccine will be a more affordable alternative to the rotavirus vaccines already on the market.

"With its low price and strong efficacy, ROTAVAC has the potential to significantly reduce the incidence of severe diarrhoea due to rotavirus among children in India," said Dr M.K. Bhan, Advisor to the Indian Academy of Pediatrics and former DBT Secretary.

The vaccine efficacy compares favourably with the efficacy of the currently licensed rotavirus vaccines in low-resource countries. The study results showed clear evidence of protection across different rotavirus strains and
'/>"/>

Contact: Allison Clifford
aclifford@path.org
202-669-7238
PATH
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Queens scientists seek vaccine for Pseudomonas infection
2. In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics
3. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
4. SFU HIV/AIDS vaccine research gets financial boost
5. Researchers identify Achilles heel of dengue virus, target for future vaccines
6. AAPS National Biotechnology Conference to highlight innovative vaccines
7. Army study: DNA vaccine and duck eggs protect against hantavirus disease
8. Sensitive test helps improve vaccine safety
9. Overweight? Theres a vaccine for that
10. Vaccine and antibiotics stabilized so refrigeration is not needed -- NIH study
11. Scripps Research Institute wins $77 million to develop AIDS vaccine center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2014)... Gauß-Allianz has admitted Johannes Gutenberg University Mainz (JGU) ... science hub continues to maintain a significant nationwide ... , "The acceptance of Johannes Gutenberg University Mainz ... a milestone in the national and international competition ... state of Rhineland-Palatinate can be proud that Mainz ...
(Date:10/15/2014)... 15, 2014 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market releases photos and video of ... on Monday October 13 th . Gino ... and angel investor Mr. Chad A. Verdi rang ... NXT-ID thanked his investors and employees "for their work and dedication ...
(Date:10/14/2014)... Like discriminating thieves, prostate cancer tumors scavenge and hoard ... But such avarice may be a fatal weakness. ... to kill prostate cancer cells by delivering a trove ... the diseased cells brimming with the mineral, leaving non-cancer ... drugs already commercially available for other uses, could soon ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Prostate cancer's penchant for copper may be a fatal flaw 2
... The ribosome can be thought of as a decryption device ... genetic code, which is delivered in the form of messenger ... of amino acids. The final assembly of amino acids into ... Without ribosomes, a cell would be unable to produce any ...
... question that can make or break their chances at reproducing: does ... Researchers from The University of Manchester and Syracuse University ... that where animals fall on the lover/fighter scale depends on how ... In species where fighting for the right to mate ...
... 2014 - Eurofins MWG Operon, a leader in ... sequencing services with the Ion Proton Next Generation ... sequencing was also awarded after joining Life Technologies ... program. Membership in Life Technologies, CSP program is ...
Cached Biology News:Mitochondrial ribosome revealed 2Mitochondrial ribosome revealed 3Mitochondrial ribosome revealed 4Does it pay to be a lover or a fighter? It depends on how you woo females 2
(Date:10/22/2014)... Physicians Choice Laboratory Services (PCLS) ... which enables healthcare providers to individualize therapeutic treatments ... results, healthcare providers are better able to assess ... minimizing risks for adverse drug reactions and interactions. ... FDA [1] more than 2.2 million adverse drug ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
(Date:10/20/2014)... Convey Computer , the leader in hybrid-core ... University won first place in the 2014 MemoCODE ... team’s solution achieved the highest overall performance in the ... finisher. , Experts from all segments of the commercial ... using a variety of design tools, hardware and software. ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... March 4 Vermillion, Inc.,(Nasdaq: VRMLD ), ... its diagnostic test programs and provided a preview,of ... the course of 2008. The,Company also released financial ... 31, 2007., "In 2007, Vermillion made significant ...
... p.m. Central European/5:30 a.m. Pacific Time,members of Cell Therapeutics, Inc.,s (CTI) (Nasdaq: CTIC ... recent,transactions targeting cleaning up the capital structure, and upcoming,product and sales milestones., ... Conference Call Numbers ... Wednesday, March 5 ...
... Imaging,Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) ... exhibit CT Laser Mammography (CTLM(R)),technology at the annual ... in Vienna, Austria. IDSI will be located at ... ), "We are pleased to be a ...
Cached Biology Technology:Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 2Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 3Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 4Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 5Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 6Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 7Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 8Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 9Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones 2CT Laser Mammography Technology to be Featured at European Congress of Radiology 2
... instrument is the most advanced thermal cycler ... thermal performance, the Dyad also boasts graphical ... point-and-click navigation via touch pad or mouse. ... and economically expanded to a four-bay system ...
... Pierce ready-to-use 2-D gel marker mix was designed ... gel marker mix contains a complement of seven ... of value to those who use markers to ... molecular weight values of proteins undergoing 2-D separation ...
... Tetrad 2 thermal cycler is a completely ... Tetrad chassis, and it accepts the full ... delivers the same precision in thermal performance ... Tetrad thermal cyclers, allowing easy transport of ...
... Engine Tetrad thermal cycler expands the ... PTC-200 DNA Engine cycler. ... with a footprint only twice the ... laboratories that run massive quantities of ...
Biology Products: